Skip to content

Trial Summary

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with either fulvestrant or letrozole + palbociclib.

Acronym:

KAT6

ACTRN/NCT /ethics:

NCT04606446

Scientific title:

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Sponsor / Cooperative group:

Pfizer

Trial & Patient Characteristics

Cancer TypeSolid tumours
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2020-11-16
Anticipated End Date2027-09-23

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead
Emailadmin@cancerresearchsa.com.au
Phone08 8359 2565
Principal InvestigatorDr Rohit Joshi
Recruitment StatusRecruiting